Online Inquiry
Cat.#: ASSD-144
| Description | Oxazole Yellow iodide, a green fluorescent DNA marker, is a carbocyanine nucleic acid stain that has a strong binding affinity to nucleic acids. It is commonly used to identify apoptotic cells. YP1 does not penetrate the plasma membrane of viable cells. However, apoptotic processes cause the cell membrane to become slightly permeable, allowing YP1 to enter these cells and bind to nucleic acids to allow detection of apoptotic cells. |
| Synonyms | Yo-Pro-1, YP1, YP-1 |
| Size | 1 mg |
| Applications | Frequently used with propidium iodide when staining for apoptotic and necrotic cells as apoptotic cells remain impermeant to propidium iodide but permeable to Oxazole Yellow (YP1). |
| Chemical Name | 4-[(3-Methyl-2(3H)-benzoxazolylidene)methyl]-1-[3-(trimethylammonio)propyl]-quinolinium diiodide |
| Molecule Weight | 629.32 |
| Molecular formula | C24H29I2N3O |
| CAS Number | 152068-09-2 |
| PubChem identifier | 6439500 |
| Purity | >99% |
| Solubility | Soluble in water (1 mg/ml), and in DMSO (1 mg/ml) |
| Form | Yellow solid |
| Storage | Store at -20° C |
| Shipping | Shipped at 4°C |
| Important | We strongly recommend storing this product away from light. |
| Cat.# | Name | Size | Price |
|---|---|---|---|
| ASSD-105 | Hoechst 33342 (AC105) | 10 mg, 100 mg | inquiry |
| ASSD-156 | Crystal Violet (AC156) | 1g, 5g | inquiry |
| ASSD-195 | 6-Aminofluorescein (AC195) | 1 g | inquiry |
| ASSD-155 | Bromophenol blue (AC155) | 5g | inquiry |
| ASSD-225 | Antifade Fluorescence Mounting Medium with Propidium Iodide (aqueous) (AC225) | 10 mL | inquiry |
| ASSD-154 | Brilliant Blue R-250 (AC154) | 1g, 5g | inquiry |
| ASSD-109 | Picro Sirius Red Solution (AC109) | 250 mL | inquiry |
| ASSD-183 | 5-(4,6-Dichloro-s-triazin-2-ylamino)fluorescein hydrochloride (AC183) | 100 mg | inquiry |
| ASSD-102 | DAPI (AC102) | 10 mg, 50 mg | inquiry |
| ASSD-185 | Cyanine 3 Maleimide, Potassium Salt (AC185) | 500 μg | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.